XML 61 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies - Additional Information (Detail) - USD ($)
 1 Months Ended 12 Months Ended
Mar. 28, 2018
Aug. 31, 2020
Feb. 29, 2020
Dec. 31, 2021
Dec. 31, 2020
Schedule Of Significant Accounting Policies [Line Items]          
Accumulated other comprehensive income to foreign currency translation       $ 841,000 $ 841,000
Marketable securities       33,000,000.0 0
Purchases of marketable securities       33,000,000.0  
Marketable securities matured       0  
Interest-bearing cash equivalent consisted of money market fund       155,600,000  
Interest-bearing cash equivalent consisted of investment-grade commercial paper       16,500,000  
Allowance for credit loss       $ 0 $ 0
Pre Funded Warrants to purchase common stock       3,272,727  
Accounting Standards Update 2019-12 [Member]          
Schedule Of Significant Accounting Policies [Line Items]          
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]       true  
Change in Accounting Principle, Accounting Standards Update, Adoption Date       Jan. 01, 2021  
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]       true  
Icon Bioscience Inc [Member]          
Schedule Of Significant Accounting Policies [Line Items]          
Percentage of accelerated milestone payment received         20.00%
DEXYCU [Member]          
Schedule Of Significant Accounting Policies [Line Items]          
Accrued revenue-based royalty expense       $ 2,500,000 $ 2,300,000
DEXYCU [Member] | Icon Bioscience Inc [Member]          
Schedule Of Significant Accounting Policies [Line Items]          
Accrued revenue-based royalty expense       $ 0 $ 1,300,000
Percentage of accelerated milestone payment received   20.00%      
Percentage of upfront payment received     20.00%    
Finite-lived intangible asset, useful life 13 years     9 years 3 months  
Minimum [Member]          
Schedule Of Significant Accounting Policies [Line Items]          
Accounts receivable standard payment terms       120 days  
Estimated useful lives of assets       3 years  
Maximum [Member]          
Schedule Of Significant Accounting Policies [Line Items]          
Accounts receivable standard payment terms       127 days  
Estimated useful lives of assets       5 years  
Investment Instruments [Member] | Credit Concentration Risk [Member] | Money Market Funds [Member]          
Schedule Of Significant Accounting Policies [Line Items]          
Percentage of concentration risk       90.40%  
Investment Instruments [Member] | Credit Concentration Risk [Member] | Commercial Paper [Member]          
Schedule Of Significant Accounting Policies [Line Items]          
Percentage of concentration risk       9.60%  
Accounts Receivable [Member] | Customer Concentration Risk [Member] | ASD Specialty Healthcare LLC [Member]          
Schedule Of Significant Accounting Policies [Line Items]          
Percentage of concentration risk       38.30% 56.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | McKesson Specialty Care Distribution LLC [Member]          
Schedule Of Significant Accounting Policies [Line Items]          
Percentage of concentration risk       54.70% 37.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | ASD Specialty Healthcare LLC [Member]          
Schedule Of Significant Accounting Policies [Line Items]          
Percentage of concentration risk       43.10% 39.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | McKesson Specialty Care Distribution LLC [Member]          
Schedule Of Significant Accounting Policies [Line Items]          
Percentage of concentration risk       46.60% 18.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Ocumension Therapeutics [Member]          
Schedule Of Significant Accounting Policies [Line Items]          
Percentage of concentration risk         33.00%